Pharmacologic treatments for covid-19 patients

Methods

Protocol

Protocol amendment:

As of December 14, 2022, the COVID-NMA revised its protocol and stopped including pharmacological interventions trials. The analysis presented in this page includes trials identified and included up to December 14, 2022. Ofnote, different last search date are considered by category. We provide the updated results up to last search defined next to each comparison including all identified reports through our search strategy up to this date.

meta-COVID

Perform your own analysis using COVID-NMA data, create and download your forest plots by clicking below:

go to metacovid

Summary of Main Results

Summary of the evidence for pharmacological treatment of hospitalized COVID-19 patients identified up to October 17, 2022 is available below.

Summary of Main Results

For earlier editions of the summary of main results, click here

Treatment comparisons

Create and download your forest plots with the most up-to-date data here Forest plots

Search by treatment name :

Display new or updated analyses

Display all results

Your research: Nirmatrelvir

Access the forest plots for the 1 treatment comparisons .

Comparisons evaluating antivirals and immunomodulators with last search date December 14, 2022.

    Anti-virals (1 comparisons)

Comparisons with last search date 28 February 2022 or as stated next to each comparison.

Search studies

Search by Author Registration number

General characteristics of primary studies

Trial Funding Comparisons Design Participants Sample size Overall risk
of bias
Highest assessment
Full description
Treatment 1 Treatment 2
NCT04960202
EPIC-HR
Hammond J, N Engl J Med, 2022
Full text
Commentary
Private

Nirmatrelvir/ritonavir

Placebo

RCT Outpatients with confirmed COVID-19 (mild) treated by 343 centers in 21 countries N=2246
Some concerns
Details

Full description